Table 2 Peptides identified by the mass mapping procedure and relative to: isolated ICOSL, isolated ICOSL + DTSSP (indicated with CL); OPN/ICOSL complex +DTSSP (indicated with CL); OPN/ICOSL + DTSSP (indicated with CL) following reduction and alkylation treatment (indicated with CAM).
Lysine Residue | Peptides from ICOSL | Peptides from (ICOSL + DTSSP) | Peptides from the complex (OPN/ICOSL + DTSSP) | Peptides from the complex (OPN/ICOSL + DTSSP) REDCAM |
|---|---|---|---|---|
N-TERM | 19–23 Exp 619.24 Theor 619.28 19–26 Exp 1003.47 Theor 1003.49 | 19–26(+1CLINTRA) Exp 1177.44 Theor 1177.49 19–26(+1CLH2O) Exp 1195.45 Theor 1195.49 | 19–26(+1CLINTRA) Exp 1177.44 Theor 1177.49 19–26(+1CLH2O) Exp 1195.45 Theor 1195.49 | 19–26(+1CL + 1CAM) Exp 1148.47 Theor 1148.49 19–26(+2CL + 2CAM) Exp 1293.47 Theor 1293.49 |
K23 | 19–26 Exp 1003.47 Theor 1003.49 | 19–26(+1CLINTRA) Exp 1177.44 Theor 1177.49 19–26(+1CLH2O) Exp 1195.45 Theor 1195.49 | 19–26(+1CLINTRA) Exp 1177.44 Theor 1177.49 19–26(+1CLH2O) Exp 1195.45 Theor 1195.49 | 19–26(+1CL + 1CAM) Exp 1148.47 Theor 1148.49 19–26(+2CL + 2CAM) Exp 1293.47 Theor 1293.49 |
K60 | 45–60 Exp 1992.86 Theor 1992.91 | 45–60 Exp 1992.86 Theor 1992.91 61–79 Exp 2158.01 Theor 2158.06 | 45–60 Exp 1992.83 Theor 1992.91 61–79 Exp 2158.00 Theor 2158.06 | – |
K110 | 100–110 Exp 1317.61 Theor 1317.66 | – | – | – |
K174 | 175–194 Exp 2307.13 Theor 2307.12 | 175–194 Exp 2307.99 Theor 2307.12 | – | – |
K241 | 240–252 Exp 1416.67 Theor 1416.71 | 240–252(+1CLH2O) Exp 1608.70 Theor 1608.71 | 240–252 Exp 1416.64 Theor 1416.71 240–252(+1CLH2O) Exp 1609.64 Theor 1609.71 | 240–252 (+1CL + 1CAM) Exp 1562.66 Theor 1562.71 |
K252 | 242–264 Exp 2626.16 Theor 2626.22 | 242–264 (+1CLH2O) Exp 2818.18 Theor 2818.22 253–264 Exp 1470.61 Theor 1470.64 | 242–264(+1CLH2O) Exp 2818.18 Theor 2818.22 253–264 Exp 1470.61 Theor 1470.64 | 253–264 Exp 1470.61 Theor 1470.64 |
